

HOT TOPICS In Buprenorphine Treatment

A webinar series offered by the American Psychiatric Association as part of the CSAT-Funded Physicians' Clinical Support System-Buprenorphine (PCSS-B)

The American Psychiatric Association offers monthly webinars for physicians who have waivers to treat Opioid dependence in office-based settings and other interested clinicians. The presentations address cutting-edge topics in treating substance use disorders and feature nationally prominent clinical experts, researchers, and government officials. Join us the **second Tuesday of each month at noon Eastern.**

DATE/TIME: Tuesday, February 14, 2012: Noon – 1 p.m. Eastern

TOPIC: Buprenorphine Treatment During Pregnancy

PRESENTER: Marjorie C. Meyer, M.D.

Associate Professor, OB/GYN

Director, Division of Maternal Fetal Medicine University of Vermont School of Medicine

REGISTER AT: www2.gotomeeting.com/register/461550554

The webinar will focus on pregnancy and the initiation and maintenance of buprenorphine for the treatment of opioid dependence during pregnancy. Dr. Meyer will discuss:

- the physiology of pregnancy
- risks/benefits of buprenorphine vs methadone
- risks of induction during pregnancy
- the team recommended for treatment of pregnant women
- dose adjustments during pregnancy
- pain control during labor and delivery

NOTE: Recordings of previous PCSS-B webinars can be accessed at www.pcssb.org Click on the Hot Topics webinars tab.

PCSS-B is operated by the American Academy of Addiction Psychiatry (lead), the American Osteopathic Academy of Addiction Medicine, and the American Psychiatric Association with funding from the Substance Abuse and Mental Health Services Administration/Center for Substance Abuse Treatment. Funding for this conference was made possible (in part) by (1H79T1022022-01) from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.